Risk of Severe COVID-19 in Non-Adherent OSA Patients.
COVID-19
CPAP adherence
OSA
treatment with CPAP
vaccination
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
08
2022
accepted:
26
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Patients with obstructive sleep apnoea (OSA) are at increased risk of severe course of COVID-19. Vaccination remains to be the most effective prevention of complicated courses of infection. The best contemporary conservative treatment of OSA is continuous positive airway pressure (CPAP) therapy. To compare vaccination acceptance and outcomes of COVID-19 infection between OSA patients adhering to the CPAP therapy and those who rejected CPAP and surgical therapy. Subjects were divided into two groups: group A (N = 167) were individuals with sufficient CPAP adherence (more than 4 hours per night on average) over the last 10 years. Group B (N = 106) were individuals who did not use the CPAP therapy at all and had no indications to surgical therapy. Three patients in group B died, and one had a severe course of COVID-19. None of the patients in group A died or experienced a severe course of COVID-19. Group A had a significantly higher proportion of males (77.8% compared to 66% in group B) and all parameters of OSA severity. The vaccination status was similar among both groups, with a complete triple dose vaccination rate of 69.5% and 67.9% in groups A and B, respectively. The results show that the patients with OSA adherent to CPAP therapy were less likely to experience a severe course of COVID-19 or death than the OSA patients non-compliant with therapy, despite the former group having more severe OSA. This result underlines the importance of adherence to CPAP therapy in OSA.
Sections du résumé
Background
UNASSIGNED
Patients with obstructive sleep apnoea (OSA) are at increased risk of severe course of COVID-19. Vaccination remains to be the most effective prevention of complicated courses of infection. The best contemporary conservative treatment of OSA is continuous positive airway pressure (CPAP) therapy.
Purpose
UNASSIGNED
To compare vaccination acceptance and outcomes of COVID-19 infection between OSA patients adhering to the CPAP therapy and those who rejected CPAP and surgical therapy.
Patients and Methods
UNASSIGNED
Subjects were divided into two groups: group A (N = 167) were individuals with sufficient CPAP adherence (more than 4 hours per night on average) over the last 10 years. Group B (N = 106) were individuals who did not use the CPAP therapy at all and had no indications to surgical therapy.
Results
UNASSIGNED
Three patients in group B died, and one had a severe course of COVID-19. None of the patients in group A died or experienced a severe course of COVID-19. Group A had a significantly higher proportion of males (77.8% compared to 66% in group B) and all parameters of OSA severity. The vaccination status was similar among both groups, with a complete triple dose vaccination rate of 69.5% and 67.9% in groups A and B, respectively.
Conclusion
UNASSIGNED
The results show that the patients with OSA adherent to CPAP therapy were less likely to experience a severe course of COVID-19 or death than the OSA patients non-compliant with therapy, despite the former group having more severe OSA. This result underlines the importance of adherence to CPAP therapy in OSA.
Identifiants
pubmed: 36387050
doi: 10.2147/PPA.S387657
pii: 387657
pmc: PMC9657257
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3069-3079Informations de copyright
© 2022 Genzor et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Clin Sleep Med. 2021 Mar 1;17(3):533-544
pubmed: 33108270
Sleep Breath. 2021 Jun;25(2):1155-1157
pubmed: 32989673
Sleep. 2019 Oct 9;42(10):
pubmed: 31587046
Sleep Breath. 2012 Sep;16(3):695-701
pubmed: 21796489
Patient Prefer Adherence. 2021 Jul 12;15:1557-1570
pubmed: 34285474
JAMA. 2012 May 23;307(20):2161-8
pubmed: 22618923
Eur Heart J. 2013 Mar;34(11):809-15
pubmed: 22427382
Sleep. 2013 Dec 01;36(12):1929-37
pubmed: 24293768
J Sleep Res. 2016 Dec;25(6):731-738
pubmed: 27242272
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Eur Respir J. 2009 May;33(5):1195-205
pubmed: 19407053
Circulation. 2011 Mar 29;123(12):1280-6
pubmed: 21403097
Am J Respir Crit Care Med. 2001 Jan;163(1):19-25
pubmed: 11208620
J Physiol Biochem. 2014 Mar;70(1):201-13
pubmed: 24122132
Auris Nasus Larynx. 2019 Aug;46(4):548-558
pubmed: 30538069
Sleep. 2007 Jun;30(6):711-9
pubmed: 17580592
J Clin Sleep Med. 2021 Nov 1;17(11):2197-2204
pubmed: 34019476
Sleep Med. 2018 Mar;43:66-70
pubmed: 29482815
Prev Med. 2021 Sep;150:106694
pubmed: 34171345
PLoS One. 2011;6(8):e22503
pubmed: 21857929
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001106
pubmed: 16855960
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Jul 2;:
pubmed: 34282803
Hypertension. 2011 Nov;58(5):811-7
pubmed: 21968750
Eur Respir J. 2020 Jul 30;56(1):
pubmed: 32430426
BMC Pulm Med. 2022 Mar 21;22(1):99
pubmed: 35313858
N Engl J Med. 2000 May 11;342(19):1378-84
pubmed: 10805822
Med Lav. 2017 Aug 28;108(4):276-282
pubmed: 28853425
Sci Rep. 2015 Nov 05;5:16160
pubmed: 26537869
Nat Sci Sleep. 2021 Jul 12;13:1097-1108
pubmed: 34290535
J Clin Sleep Med. 2016 Feb;12(2):169-76
pubmed: 26350607
Sleep. 2021 Feb 12;44(2):
pubmed: 33165616
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):277-82
pubmed: 25559094
Intern Med J. 2012 Jun;42(6):e95-101
pubmed: 21040323